Sorafenib and triptolide as combination therapy for hepatocellular carcinoma

Alsaied, Osama; Sangwan, Veena; Banerjee, Sulagna; Krosch, Tara C.K.; Chugh, Rohit; Saluja, Ashok K.; Vickers, Selwyn M.; Jensen, Eric H.

doi:10.1016/j.surg.2014.04.055

Cited by 60 publications

(41 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…94 The receptor-mediated endocytosis is the main mechanism of the cellular internalization through folate receptors (FRs) with a high affinity (K D ~10 -10 M). 96 Natural product triptolide has been proved to be highly effective against many tumor cells including cholangiocarcinoma, 97 pancreatic cancer, 98 HCC, 99 and so on. However, the clinical applications have been limited by poor solubility and extreme side effects.…”

Section: Vitamin-based Active Targetingmentioning

confidence: 99%

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Li¹,

Zhang²,

Wang³

et al. 2016

IJN

118

View full text Add to dashboard Cite

Section: Vitamin-based Active Targetingmentioning

confidence: 99%

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Li¹,

Zhang²,

Wang³

et al. 2016

IJN

118

View full text Add to dashboard Cite

“…MCF-7 cells, carrying ERalpha-positive and wild-type p53 gene, was much sensitive to triptolide than that of MDA-MB-231 cells that carrying ERalpha-negative and mutant-p53 gene. The differential activity of triptolide on these two cell lines was evidenced by lower magnitude of IC 50 values, more fragmented nuclei and only slightly S-phase arrest on cell cycle distribution in MCF-7 cells and no sub-G0/G1 peak Figure 4. All these data suggested that triptolide can effectively inhibit the proliferation and induce apoptosis in established breast cancer cell lines.…”

Section: Effect Of Triptolide On Nf-kb Signaling Pathwaymentioning

confidence: 99%

“…[48][49][50][51][52][53] Recent reports indicated that triptolide could effectively reduce the dose of many popular anti-cancer drugs. Lin and coworkers showed that triptolide and amino terminal fragment (ATF) of urokinase (uPA) synergistically reduced the growth of breast cancer cells MDA-MB-435.…”

Section: Combination Therapymentioning

confidence: 99%

Triptolide Mediated Amelioration of Breast Cancer via Modulation of Molecular Pathways

Sarkar

Paul

2017

View full text Add to dashboard Cite

Triptolide is the main bioactive molecule isolated from a root extract of Tripterigium wilfordii Hook F. of Celastraceae family. Chemically, it is a diterpenoid triepoxide molecule and its chemical formula is C 20 H 24 O 6 . Its five-membered unsaturated lactone ring (D-ring) is crucial for anti-tumor potential and carbonyl group at C-18 position is essential to exert important influence on the interaction between triptolide and the targeted protein(s). It is bio-synthesized from deoxy-D-xylullose-5-phosphate (DOXP) pathway in the cell. Triptolide can induce apoptosis in a number of breast cancer cells by up-regulating different pro-apoptotic and down-regulating different anti-apoptotic molecules. In vitro experiments indicate that it can down regulate several cell cycle related genes and induces S-phase cell cycle arrest. Triptolide treatment can also modulate the expression of different cell signaling molecules, e.g. ERK, NF-κB, FAK, VEGF, β-catenin, AKT etc. In vivo experiments indicate that triptolide can effectively reduce breast tumor growth in the mouse model. Apart from the single drug treatment, triptolide can effectively be applied in combination therapy. Application of Triptolide with other chemotherapeutic drugs, very efficiently check the proliferation of tumor cells which reduces the effective concentration of the commercially available drugs thus reducing their toxic sideeffects. Although triptolide is very effective against a number of diseases, its higher degree of multi-organ toxicity limits its use of further clinical trial. Therefore, to reduce the toxic effects, a number of strategies have been developed which increase its water solubility and at the same time decrease the toxic effect. In this review article, we have addressed how triptolide participates in the antitumor processes in breast can cer cells.

show abstract

“…Current treatment regimens often are not effective because of the late stage of diagnosis and the inability to deliver the correct therapeutic dose to the liver [2]. Over the past few years, more effort has been concentrated in the development of multifunctional [3,4,5] or combination therapy [6,7,8] in order to improve existing anticancer treatments. This strategy has previously identified that combination therapy can result in synergy and overall can improve efficacy of therapies, as well as reduced drug resistance.…”

Section: Introductionmentioning

confidence: 99%

Dual Acting Polymeric Nano-Aggregates for Liver Cancer Therapy

et al. 2018

View full text Add to dashboard Cite

Liver cancer treatments are often hindered by poor drug physicochemical properties, hence there is a need for improvement in order to increase patient survival and outlook. Combination therapies have been studied in order to evaluate whether increased overall efficacy can be achieved. This study reports the combined treatment of liver cancer cells with a combination treatment of chemotherapeutic agent paclitaxel and pro-apoptotic protein cytochrome C. In order to administer both agents in a single formulation, a poly(allylamine)-based amphiphile has been fabricated with the incorporation of a hybrid iron oxide-gold nanoparticle into its structure. Here, the insoluble paclitaxel becomes incorporated into the hydrophobic core of the self-assemblies formed in an aqueous environment (256 nm), while the cytochrome C attaches irreversibly onto the hybrid nanoparticle surface via gold-thiol dative covalent binding. The self-assemblies were capable of solubilising up to 0.698 mg/mL of paclitaxel (700-fold improvement) with 0.012 mg/mL of cytochrome C also attached onto the hybrid iron oxide-gold nanoparticles (HNPs) within the hydrophobic core. The formulation was tested on a panel of liver cancer cells and cytotoxicity was measured. The findings suggested that indeed a significant improvement in combined therapy (33-fold) was observed when compared with free drug, which was double the enhancement observed after polymer encapsulation without the cytochrome C in hepatocellular carcinoma (Huh-7D12) cells. Most excitingly, the polymeric nanoparticles did result in improved cellular toxicity in human endothelian liver cancer (SK-hep1) cells, which proved completely resistant to the free drug.

show abstract

Sorafenib and triptolide as combination therapy for hepatocellular carcinoma

Cited by 60 publications

References 32 publications

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

Triptolide Mediated Amelioration of Breast Cancer via Modulation of Molecular Pathways

Dual Acting Polymeric Nano-Aggregates for Liver Cancer Therapy

Contact Info

Product

Resources

About